Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
暂无分享,去创建一个
Amit N. Patel | T. Henry | S. Desai | M. Mehra | S. Kuy | Sreyram Kuy
[1] K. Harmon,et al. Comorbid Medical Conditions in Young Athletes: Considerations for Preparticipation Guidance During the COVID-19 Pandemic , 2020, Sports health.
[2] Christophe G. Lambert,et al. Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study , 2020, medRxiv.
[3] N. Soudani,et al. Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling , 2020, Frontiers in Pharmacology.
[4] M. Fralick,et al. Good things come in threes (and sometimes fours): Update on renin–angiotensin–aldosterone system inhibitors and COVID-19 , 2020, Canadian Medical Association Journal.
[5] A. Zhernakova,et al. Lack of Association Between Genetic Variants at ACE2 and TMPRSS2 Genes Involved in SARS-CoV-2 Infection and Human Quantitative Phenotypes , 2020, Frontiers in Genetics.
[6] T. Walther,et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts , 2020, European heart journal.
[7] Tao Guo,et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.
[8] G. Oudit,et al. Angiotensin Converting Enzyme 2: A Double-Edged Sword. , 2020, Circulation.
[9] W. Gong,et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.
[10] A. Verma,et al. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? , 2020, JAMA.
[11] F. Ruschitzka,et al. COVID-19 Illness and Heart Failure , 2020, JACC: Heart Failure.
[12] Mandeep R. Mehra,et al. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal , 2020, The Journal of Heart and Lung Transplantation.
[13] Sharukh Lokhandwala,et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. , 2020, JAMA.
[14] Michael Roth,et al. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.
[15] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[16] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[17] Qiurong Ruan,et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.
[18] Young-Jun Park,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[19] X. Li,et al. The vasoprotective axes of the renin‐angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases , 2017, Pharmacological research.
[20] P. T. Ten Eyck,et al. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection , 2017, The Journal of Immunology.
[21] S. Klein,et al. Sex differences in immune responses , 2016, Nature Reviews Immunology.
[22] Kazuhiko Ito,et al. Seasonal Influenza Infections and Cardiovascular Disease Mortality. , 2016, JAMA cardiology.
[23] D. Diz,et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.
[24] N. Hooper,et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. , 2004, The Biochemical journal.
[25] D. Chong,et al. Do Men Have a Higher Case Fatality Rate of Severe Acute Respiratory Syndrome than Women Do? , 2004, American journal of epidemiology.
[26] World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance , 2020 .